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Background: The objective of this study was to discover and to validate novel noninvasive biomarkers that distinguish
between benign prostate hyperplasia (BPH) and localized prostate cancer (PCa), thereby helping to solve the diagnostic
dilemma confronting clinicians who treat these patients.
Methods: Quantitative iTRAQ LC/LC/MS/MS analysis was used to identify proteins that are differentially
expressed in the urine of men with BPH compared with those who have localized PCa. These proteins were
validated in 173 urine samples from patients diagnosed with BPH (N = 83) and PCa (N = 90). Multivariate logistic
regression analysis was used to identify the predictive biomarkers.
Results: Three proteins, β2M, PGA3, and MUC3 were identified by iTRAQ and validated by immunoblot analyses.
Univariate analysis demonstrated significant elevations in urinary β2M (P < 0.001), PGA3 (P = 0.006), and MUC3 (P = 0.018)
levels found in the urine of PCa patients. Multivariate logistic regression analysis revealed AUC values ranging from 0.618
for MUC3 (P = 0.009), 0.625 for PGA3 (P < 0.008), and 0.668 for β2M (P < 0.001). The combination of all three
demonstrated an AUC of 0.710 (95% CI: 0.631 – 0.788, P < 0.001); diagnostic accuracy improved even more when these
data were combined with PSA categories (AUC = 0.812, (95% CI: 0.740 – 0.885, P < 0.001).
Conclusions: Urinary β2M, PGA3, and MUC3, when analyzed alone or when multiplexed with clinically defined
categories of PSA, may be clinically useful in noninvasively resolving the dilemma of effectively discriminating between
BPH and localized PCa.
Keywords: Non-invasive biomarkers, Benign prostate hyperplasia, Prostate cancerBackground
Prostate cancer (PCa) is the second most frequently diag-
nosed form of cancer in the world and the sixth most
deadly form of male cancer [1] worldwide. In 2013, in the
United States alone, it is projected that prostate cancer will
account for 28% (238,590) of cancer cases and 10% (29,720)
of cancer deaths [2]. Benign prostatic hyperplasia (BPH) is
the most common benign disease among men worldwide
and its incidence increases with age. PCa and BPH are
common diseases of the aging male [3] and share similar* Correspondence: marsha.moses@childrens.harvard.edu
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unless otherwise stated.symptoms of frequent urination, nocturia, hematuria,
dysuria, difficulty starting and maintaining a steady stream
of urine, erectial dysfunction, and painful ejaculation [4-8].
An elevated serum prostate-specific antigen (PSA) can be
detected with either benign or malignant growth of the
prostate. It is the demographic overlap of BPH and prostate
cancer, and the lack of discrimination between these
two prostate diseases by PSA, that defines the diagnostic
dilemma clinicians face when treating prostate disease.
The PSA test has been widely used as a diagnostic,
screening, and monitoring tool since it was first approved
by the US Food and Drug Administration in 1986 as an aid
for the early detection of prostate cancer [9]. However, this
test lacks high sensitivity and specificity for PCa and PSA
levels are frequently elevated in benign conditions,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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between benign and malignant prostate growth. The Pros-
tate Cancer Prevention Trial, conducted on 2950 men, re-
ported that men who had never had a PSA greater than
4.0 ng/mL and who had normal digital rectal exams had a
prostate cancer prevalence of 15.2% in this population [11].
Even patients with the lowest PSA levels (up to 0.5 ng/mL)
had a prevalence of prostate cancer of 6.6%. While the risk
of prostate cancer increases with PSA level, it does not reli-
ably discriminate between benign and malignant disease.
For PSA levels between 4.1 to 10.0 ng/mL, the positive pre-
dictive value (PPV) for prostate cancer is 25% and, for PSA
levels greater than 10 ng/mL, reported PPVs have ranged
from 42 to 64% [12,13]. This leads to a situation in which
men with indolent disease or BPH continue to be overdiag-
nosed and unnecessarily biopsied [14]. Side effects of pros-
tate biopsies have been associated with infection, bleeding,
urinary difficulty, fever, urinary retention, prostatitis, uro-
sepsis, hematuria, and hematospermia [15]. A variety of
permutations of PSA have been utilized to attempt to en-
hance the diagnostic sensitivity and specificity of PSA
screening. However, age-adjusted PSA ranges, PSA velocity,
PSA density, and free PSA fraction have all been disap-
pointing in their ability to discriminate between BPH and
prostate cancer [16], making it very difficult to differentiate
between these two diseases in a clinical setting. In May of
2012, the United States Preventive Services Task Force
(USPSTF) announced that PSA screening for prostate can-
cer demonstrated small potential benefit against a backdrop
of potential harms [17], including misdiagnosis.
The early differential diagnosis between BPH and pros-
tate cancer is essential given the fact that both the outcome
and the treatment of these two prostatic diseases are dis-
tinct [18]. Currently, prostate cancer prognosis is based on
age, elevated levels of PSA, and a prostatic digital rectal
examination (DRE) often followed by prostate biopsy [19],
none of which can distinguish between BPH and prostate
cancer [18]. There is, therefore, an urgent need for novel
biomarkers that can effectively distinguish between pa-
tients with BPH vs. PCa.
The goal of this study was to identify and validate non-
invasive urinary biomarkers that distinguish between BPH
and localized PCa. With the advantage of being in direct
continuity with the prostatic lumen, urine represents a
body fluid that is enriched with proteins from PCa cells
[19] making it useful source of proteins for biomarker dis-
covery. In addition, urine-based tests are truly noninvasive
[20] and more easily accessible than other methods, includ-
ing blood.
Methods
Urine collection and processing
This study was approved, and urine collected, according
to the institutional bioethical guidelines of the InstitutionalReview Board at the Brigham and Women’s Hospital
(Boston). Samples were obtained in the Urology Clinic
at the Brigham and Women’s Hospital (Boston) before
surgical or other therapeutic interventions. All partici-
pants gave informed consent. The diagnosis of BPH
was made on the basis of clinical parameters which in-
cluded a normal DRE and either a normal PSA level or
a prior negative prostate biopsy if the PSA was ele-
vated. The diagnosis of prostate cancer was made only
in those patients who had confirmatory positive biop-
sies without evidence of metastatic disease. The pa-
tients diagnosed with BPH were followed up for
5 years and were declared prostate cancer free. Sam-
ples were collected in sterile containers as voided
urine and immediately frozen at −20°C and stored as
previously reported [21]. Urine was tested for the pres-
ence of blood and leukocytes using Multistix 9 strips
(Siemens Healthcare Diagnostics Inc., Tarrytown, NY),
and samples containing blood or leukocytes were ex-
cluded [21]. None of the patients had clinical signs or
documentation of prostatitis or UTI.
One hundred seventy-three (173) samples were ana-
lyzed in this study, including samples from patients diag-
nosed with benign prostate hyperplasia (n = 83) and
prostate cancer (n = 90). Specimens taken from patients
with localized cancers were obtained prior to surgical or
other therapeutic intervention. The two groups were not
significantly different with respect to race (% Caucasian:
BPH 80%, PCa 74% P = 0.11, chi-square test). Gleason
scores of the prostate adenocarcinomas ranged from 5
to 9, with 85 out of the 90 (94%) prostate adenocarcin-
omas having Gleason scores of 5–7. We had one patient
who was graded as having a Gleason score 5 by the
pathologist. This was very early in the series. The pros-
tate cancer group included stages T1-T3 with only one
patient diagnosed as a T1a stage on TURP. None of the
patients were diagnosed with metastatic cancer at the
time of sampling. Mean age was not significantly differ-
ent between the PCa and BPH and PCa groups (63.3 vs.
66.1 years, P = 0.15) as reported in Table 1. Samples were
analyzed in a double-blinded manner.
LC/LC/MS/MS identification of differentially expressed
proteins by isobaric tagging with iTRAQ (isobaric tags for
relative and absolute quantitation)
iTRAQ is a state-of-the-art quantitative mass spectrom-
etry approach to identify and quantify components of
the proteome present in biological samples. Proteins
were obtained from human urine by organic precipita-
tion with methanol following our previously published
method [22]. Protein profiling was performed using the
8-plex iTRAQ (AB Sciex, Foster City, CA) labeling
protocol and standard MudPIT methodology coupled
with the 4800 MALDI TOF/TOF Plus instrument to
Table 1 Characteristics of study groups
Characteristics Number of PCa patients (%) Number of BPH patients (%)
Number of patients 90 83
Age, years, mean ± SD 66.1 ± 8.4 63.3 ± 8.7
Race
Caucasian 67 (74.44) 66 (79.5)
Black 10 (11.1) 5 (6.0)
Other 13 (14.44) 12 (14.4)
Ethnicity
African-american 3 (3.3) 4 (4.8)
Hispanic 5 (5.55) 0 (0)
Unknown 57 (63.3) 47 (56.6)
Other 25 (27.7) 32 (38.55)
Biopsy grade
Gleason 5 1 (1.11)
Gleason 6 47 (52.22)
Gleason 7 37 (41.11)
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[22]. Protein Pilot 2.0.1 software with the Paragon algo-
rithm [23] was used for peptide and protein identifica-
tion and relative quantitation based on the iTRAQ labels
(Additional file 1).
Immunoblot analyses
All 173 urine samples (BPH = 83, PCa = 90) were individu-
ally concentrated using an UltraFree-4 centrifugal filter
device with a molecular weight cut off of 5 kDa (Millipore,
Bedford, MA, USA) as previously reported [21,24]. Protein
expression was detected by immunoblot analyses using
monospecific primary antibodies: apoD, β2M, pepsin A,
uromodulin, ZAG, (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and MUC3 (Thermo Fisher Scientific Inc,
Rockford, IL, USA). Proteins were evaluated via quantita-
tive densitometry and expressed in densitometric units
(DU) (Additional file 1).
Pathways and interactive network systems biology
analysis
Ingenuity Pathway Analysis (IPA 7.0) (http//www.ingenuity.
com) was used to identify key interaction networks andpathways significantly enriched in BPH and PCa urine
samples. Based on the differentially expressed proteins, we
built a network composed of interactive proteins using
the network building and growing utility in the Ingenuity
Pathway Analysis (IPA) tool. Enriched pathways within
this hierarchical network were ranked using the ratio of
affected proteins and Fisher’s exact test. To identify the key
regulatory molecules within this integrated network, we
used the density of maximum neighborhood component
(DMNC) algorithm [25].
Statistical analysis
Univariate analysis included a comparison of median
levels of the six proteins and PSA between PCa and BPH
patients by the nonparametric Mann–Whitney U-test
since these variables showed some skewness and lack
of normality as tested by the Kolmogorov-Smirnov
goodness-of-fit statistic. Receiver operating characteristic
(ROC) curve analysis was applied to determine the area
under the curve (AUC) as a measure of predictive accur-
acy and the Youden J-index was used to identify the
optimal cutoff value for each biomarker [26]. Multivariate
logistic regression analysis using backward selection with
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to identify the independent predictive biomarkers of PCa
and derive the probability of PCa based on combinations
of these biomarkers (using the optimal cutoff value in
densitometric units) and stratified by PSA level based on
three clinical categories (0–4, 4.1-10, >10 ng/ml). AUC
was also calculated for combinations of biomarkers with
95% confidence intervals to determine whether improved
prediction was achieved by combining significant bio-
markers together using multivariate modeling with the
c index used to quantify the combined predictive accur-
acy [27]. ROC curves were compared by the DeLong test
[28]. Two-tailed values of P < 0.05 were considered statis-
tically significant. Statistical analysis was performed using
IBM SPSS Statistics (version 21.0, IBM, Armonk, NY).
This study was conducted and its results reported in
accordance with the REMARK guidelines [29].
Results
We utilized iTRAQ LC/LC/MS/MS as our technique of
choice to sensitively and accurately identify the urinary
proteome of men with BPH vs. PCa. This approach iden-
tified 25 proteins that were differentially expressed, both
at a significant level and with high confidence, in urines
from men from each of the two groups of interest (PCa
and BPH) (Figure 1). We then performed functional
enrichment analysis and pathways enrichment analysis
of these proteins using Ingenuity Pathway Analysis (IPA)
tools to determine differentially expressed pathways and
functions in PCa as compared to BPH. These proteinsFigure 1 Urinary proteins significantly differentially expressed between BPH
shown with a pseudo color scale (−3 to 3), with red denoting up-regulation an
the rows represent the proteins.represent a number of different functional categories
including cell assembly and organization, cell signaling,
cell morphology, carbohydrate metabolism, cellular growth
and proliferation, lipid metabolism, androgen and estrogen
metabolism, and DNA replication, recombination, and re-
pair, among others (Additional file 2: Figure S1). Addition-
ally, network analysis identified differences in many focus
hubs (e.g. NFκB, ERK1/2, Collagen, TGFβ, PI3K, and p38
MAPK) with a high degree of interactivity (Figure 2).
25 proteins were differentially expressed in the urine
of patients diagnosed with BPH vs. PCa as originally
identified by iTRAQ (Figure 1). Given that enzyme-
linked immunosorbent assays (ELISA) for these proteins
were not available, nine proteins were tested based on
the availability of antibodies. Of these nine, six proteins
were validated: β-2-microglobulin (β2M), pepsinogen 3,
group 1 (PGA3), intestinal mucin (MUC3), apolipo-
protein D (APOD), alpha-2-glycoprotein 1, zinc (ZAG),
and uromodulin (THP) (Figure 3).
Univariate analysis was performed to compare BPH
and PCa groups with respect to age and each of the six
validated urinary biomarkers (Table 2). These compari-
sons, based on continuous data of the six validated pro-
teins, revealed significant elevations in β2M (P < 0.001),
PGA3 (P = 0.006), and MUC3 25 kDa (P = 0.018). We
then identified the optimal cut-off values using ROC
analysis with the Youden index for each of three signifi-
cant urinary biomarkers, and the analysis indicated ≥ 40
DU for β2M, ≥ 190 DU for PGA3, and ≥ 185 DU for
MUC3. Multivariate logistic regression modeling wasvs. PCa identified by iTRAQ. The relative level of protein expression is
d green denoting down-regulation. The columns represent samples and
Figure 2 Interactive network of the proteins that are differentially expressed in prostate cancer as compared to BPH. The network node and edges
represent proteins and their interactions respectively. The intensity of the node color indicates the degree of up-regulation (red) or down-regulation
(green), while white nodes indicate non-modified proteins that may be affected by post-translational modification. All networks shown were significantly
affected in prostate cancer, with a score >15. The network analysis identified many focus hubs (e.g. NFκB, ERK1/2, Collagen, TGFβ, PI3K, p38 MAPK)
with high degree of interactions.
Figure 3 Immunoblot analyses of urine samples from BPH and
prostate cancer patients. Representative urine samples were separated
on 4-12% Bis-Tris gels under reducing conditions and were subsequently
subjected to western blot analysis using the appropriate antibody for the
following iTRAQ-identified proteins: mucin 3 fragment (MUC3 25 kDa),
mucin 3 fragment (MUC3 51 kDa), β-2-microglobulin (β2M), pepsinogen
3 (PGA3), apoliprotein D (ApoD), alpha-2-glycoprotein 1, zinc (ZAG) and
uromodulin (THP). One hundred seventy-three (173) urine samples from
patients diagnosed with benign disease (N = 83) and tumor disease
(N = 90) were analyzed.
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of the three significant biomarkers in the univariate
analysis as well as for PSA (using three clinically defined
categories: 0–4 ng/mL, 4.1-10 ng/mL, >10 ng/mL). The
probability of PCa was determined using multivariate
logistic regression modeling according to each of three
urinary biomarkers (β2M, PGA3, MUC3) as well as PSA
in the predictive model. Having determined the optimalTable 2 Comparison of Age and Urinary Proteins Between
PCa and BPH Cohorts
Variable PCa BPH
(N = 90) (N = 83) AUC P value
Age, years, mean 63.3 ± 8.7 66.1 ± 8.4 – 0.15
β2M 143.4 (44.5-289.8) 30.3 (4.2-194.6) 0.658 <0.001*
PGA3 198 (32–329) 106 (8–263) 0.623 0.006*
MUC3 25 kDa 421 (239–490) 322 (93–465) 0.605 0.018*
MUC3 51 kDa 33.0 (6.3-104.9) 18.7 (3.2-68.4) 0.583 0.06
APOD 381 (134–512) 255 (35–486) 0.568 0.14
THP 267 (122–368) 232 (89–377) 0.547 0.30
ZAG 384 (144–529) 351 (89–523) 0.522 0.64
Biomarker data are median (interquartile range) of densitometric units (DU).
AUC = area under the curve. * Statistically significant.
Figure 4 Probability of PCa according to urinary biomarkers
stratified by PSA level: A) Probability of PCa according to β2M
stratified by PSA level, β2M≥ 40 DU (P <0.001) B) Probability of PCa
according to β2M stratified by PSA level, PGA3≥ 190 DU (P = 0.008)
B) Probability of PCa according to PGA3 stratified by PSA level C)
Probability of PCa according to MUC3 stratified by PSA level,
MUC3≥ 185 DU (P = 0.009).
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index in receiver operating characteristic (ROC) curve
analysis, we chose to use the binary predictors (i.e.,
above and below each cut-off ) stratified according to
clinically relevant categories of PSA. The probabilities
shown in each panel of Figure 4 are based on two levels
of the biomarker for each of three PSA categories (0–4,
4.1-10, >10 ng/mL). The multivariate modeling strategy
uses the Newton–Raphson algorithm in maximum likeli-
hood estimation (MLE) to derive the probability of PCa
based on combinations of the biomarkers within each
PSA category. Figure 4 illustrates that the estimated
probability of PCa within each PSA category is signifi-
cantly higher in patients who are above the cut-off value
for the biomarker and that the probability of PCa is ele-
vated with increasing PSA. ROC analyses revealed that if
the levels of β2M are less than 40 DU, the PGA3 levels
are less than 195 DU and the MUC3 levels are less than
185 DU, the predictive accuracy is improved to 45%,
53%, and 45%, respectively. However, when the DU
levels are equal to, or higher than, 40 DU of β2M, 195
DU of PGA3 and 185 DU of MUC3, the diagnostic ac-
curacy is significantly improved to 74%, 77% and 72%,
respectively (Figure 4). In addition, the ROC clearly
shows a steeper curve for the three urinary biomarkers
(MUC3, PGA3, β2M), as well as for the three bio-
markers and the PSA categories (Figure 5).
To determine the predictive accuracy of each of the
significant independent multivariate biomarkers based
on the optimal cutoff values and PSA based on the three
categories, we used ROC analysis to assess the AUC for
single biomarkers and the combination of three with
and without PSA (Table 3). Single biomarkers had AUC
values ranging from 0.618 for MUC3 25 kDa (P = 0.009)
to 0.668 for β2M (P < 0.001); the combination of β2M,
PGA3 and MUC3 25 kDa increased the AUC to 0.710
(95% CI: 0.631 – 0.788, P < 0.001). Predictive accuracy
was 0.734 based on PSA categories alone and signifi-
cantly increased to 0.812 for the three biomarkers com-
bined with PSA categories (P = 0.004, Delong test for
comparing ROC curves). False positive (FPR) and false
negative rates (FNR) are highly relevant in clinical
practice and we have evaluated the FPR and FNR for
each of the three significant multivariate predictive bio-
markers in differentiating between BPH and PCa. It is
clear that compared to each of the three urinary bio-
markers alone, our combined panel of three biomarkers
provide much lower FPRs and FNRs based on all pa-
tients in the study population. The primary objective of
this study was to identify the best set of urinary bio-
markers to improve diagnostic accuracy in differentiat-
ing between BPH and PCa; the misclassification rates
shown above underscore the value of a panel of bio-
markers rather than any one biomarker in isolation.The combination of three biomarkers together (β2M,
PGA3, MUC3) shows an FPR of 30% in conjunction
with a very low FNR range of 0% to 8%, making this
combination potentially useful in a clinical setting.
Figure 5 Receiver operating characteristic curves for combined
urinary biomarkers in differentiating BPH patients from PCa patients.
White circles represent the ROC curve (AUC = 0.734) for three
clinically relevant PSA categories (0–4, 4.1-10, >10 ng/mL). Black
triangles signify the ROC curve based on the combination of three
urinary biomarkers with PSA categories and demonstrate the highest
diagnostic accuracy (AUC = 0.812), representing significant
improvement (P = 0.004).
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This study was designed to evaluate new markers in a
patient population that would undergo screening in
common clinical practice. The U.S. Preventive Task
Force has rejected the utility of PSA screening for pros-
tate cancer and this study was designed to determine if
new urinary markers would be more informative in dis-
criminating between BPH and prostate cancer which is
the problem facing clinicians. Neither PSA nor these
urinary markers are intended to discriminate between
indolent versus aggressive prostate cancer, they are not
intended to be utilized to identify “normal” men who
have neither BPH nor prostate cancer. The clinical chal-
lenge is differentiating BPH from prostate cancer. Al-
though transition zone cancers can account for 10-20%
of prostate cancers, they are not normally diagnosed
with typical initial screening strategies. They are usually
considered when one or more initial sets of routine
transrectal biopsies have been negative for prostateTable 3 Diagnostic accuracy of biomarkers in predicting PCa
Biomarker AUC
β2M≥ 40 DU 0.668
PGA3≥ 190 DU 0.625
MUC3≥ 185 DU 0.618
PSA categories, ng/mL (0–4.0, 4.1-10, >10) 0.734
β2M + PGA3 + MUC3 0.710
β2M + PGA3 + MUC3 + PSA categories 0.812
AUC = area under the curve; CI = confidence interval, DU = densitometric unit. * Detcancer and clinical suspicion persists, and such patients
often undergo MRI imaging and more extensive biopsy
regimens. These patients were not included in our rou-
tine screening population.
In recent years, urinary biomarkers have emerged as
an attractive option for the noninvasive detection of PCa
[21,30-32]. Given the complexity of this disease, it is
now widely appreciated that a single marker may not ne-
cessarily reflect the multifactorial nature of BPH or PCa
[30]. A panel, rather than any individual biomarker, will
have a higher likelihood to more accurately distinguish
between BPH and localized PCa in conjunction with
clinico-pathological parameters. This panel of three
newly identified biomarkers β2M, PGA3, and MUC3 ef-
fectively discriminated BPH from localized PCa.
The first protein found to be significantly elevated in
urine of PCa patients was mucin 3 (MUC3), a member of
the membrane-associated mucins, which may be shed from
the cell surface via activation of membrane-associated me-
talloproteinases [33-35]. Previous studies reported a correl-
ation between elevated MUC3 expression and esophageal
[36], gastric [37], breast [38], and colon cancers [39]. We
found that MUC3 was able to differentiate between BPH
and localized PCa. In addition, this ability of MUC3 to dis-
criminate between BPH and localized PCa was strength-
ened when MUC3 was multiplexed with clinically-defined
categories of PSA, making it a prospective biomarker for
differentiating BPH from localized PCa.
We also found Pepsinogen 3, group 1 (PGA3) to be ele-
vated in the urine of PCa patients but not in BPH. PGA3 is
synthesized and secreted by the gastric chief cells of the
human stomach before being converted into the proteo-
lytic enzyme pepsin A, an upstream step in the digestive
process [40]. Low levels of PGA in serum [41], as well as
decreased or lost expression of PGA in gastric tissue and
cancer cell lines, were previously reported [42]. In contrast,
a recent study demonstrated increased mRNA levels of
PGA in seven colorectal cancer cell lines [43]. Interestingly,
our study is the first to report that PGA3 can be used to
effectively distinguish between patients with BPH or with
localized PCa.
Lastly, β2M, a component of the major histocompati-
bility complex class I (MHC I), was the third proteinbased on optimal cutoff values from ROC analysis*
95% CI P value
0.628 – 0.748 <0.001*
0.547 – 0.710 0.008*
0.532 – 0.700 0.009*
0.653 – 0.814 0.007*
0.631 – 0.788 <0.001*
0.740 – 0.885 <0.001*
ermined by the Youden index.
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lysis. Increased expression of β2M has been previously
associated with breast [44], renal [45], lung [46], colon
[47], and hematologic malignancies [48]. β2M levels
were also significantly elevated in urine [49] and in
serum [50] of prostate cancer patients when compared
to healthy subjects. Ours is the first study demonstrat-
ing that β2M effectively discriminates between BPH
and localized of PCa.
Conclusions
This comprehensive iTRAQ LC/LC/MS/MS analysis,
followed by extensive validation of the candidate urinary
biomarkers, revealed that β2M, PGA3, and MUC3 can sen-
sitively and specifically differentiate between patients with
BPH and localized prostate cancer. When these markers
are multiplexed, their accuracy in differentiating between
BPH and localized PCa is further increased. Importantly,
this small panel of biomarkers, when multiplexed with
clinically defined categories of PSA, effectively distin-
guishes BPH from localized PCa with high sensitivity
and specificity. In summary, noninvasive urine tests
utilizing β2M, PGA3 and MUC3, in conjunction with
clinically defined categories of PSA, have the potential
to significantly enhance the ability to discriminate be-
tween BPH and localized PCa in the clinical setting.
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